Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects

A G Harris

Abstract

Somatostatin is a 14 amino acid peptide that inhibits pancreatic exocrine and endocrine secretion. Its clinical application has been limited by its very short half life, necessitating continuous intravenous infusion. Octreotide is an 8 amino acid synthetic analogue of somatostatin that possesses similar pharmacological effects. It has a much longer duration of action, however, and can be given subcutaneously. Both the intravenous and subcutaneous routes of injection of octreotide are well tolerated. Peak serum concentrations occur within 30 minutes after subcutaneous administration and within four minutes of a three minute intravenous infusion. Serum concentration increases linearly with dose. Octreotide is distributed rapidly, mainly in the plasma, where it is 65% protein bound. The elimination half life is about 1-5 hours and about 32% of a subcutaneous dose is excreted in the urine as unchanged octreotide. Octreotide inhibits gastrointestinal secretion, especially of insulin, glucagon, pancreatic polypeptide, gastric inhibitory polypeptide, and gastrin. It also inhibits both release of thyroid stimulating hormone and growth hormone secretion in response to exercise, insulin induced hypoglycaemia, and arginine stimulation. Octreotide reduces splanchnic blood flow in healthy volunteers and hepatic venous pressure in cirrhotic patients. It can accelerate or delay gastric emptying, prolong transit time at moderate to high doses, stimulate motility at low doses, and inhibit gall bladder emptying. Octreotide considerably inhibits pentagastrin stimulated gastric acid secretion and significantly diminishes exocrine pancreatic function (amylase, trypsin, lipase). Octreotide increases intestinal transit time and decreases endogenous fluid secretion in the jejunum and ileum, thus increasing the absorption of water and electrolytes. These pharmacological effects of the analogue point to its therapeutic role in a variety of endocrine and gastrointestinal disorders.

(Gut 1994; supplement 3: S1-S4)

The somatostatin family

NATIVE MOLECULAR STRUCTURES

Somatostatin is the name given to a family of peptides, the original member of which, somatostatin 14, a tetradecapeptide, was first isolated from ovine hypothalami by Roger Guillemin’s group at the Salk Institute, in the course of an unsuccessful search for growth hormone releasing factor. The molecule was shown to inhibit growth hormone release from cultured pituitary cells, and for a while was known variously as growth hormone releasing factor, somatostatin releasing inhibiting factor, and growth hormone release inhibiting factor, until somatostatin – proposed by the Salk group in a note to the original article – emerged as standard.

The native molecule was found to have a cyclic structure joined by two intramolecular disulphide bonds between the two cysteine residues (Figure). The linear reduced sequence, however, proved to have the same biological activity as the cyclic form in vitro – that is, the cyclic form was not essential for recognition by specific somatostatin receptors.

A second native form of somatostatin was reported in 1980. Somatostatin 28 contains the amino acid sequence of somatostatin 14, extended by 14 residues at the N-terminus. Though there is some evidence that somatostatin 28 may act as a precursor, it also operates as a hormone in its own right, with a slightly different spectrum of activity in different tissues. Thus somatostatin 28 suppresses growth hormone for much longer, but is less effective in suppressing gastric acid. There is virtually no somatostatin 28 in the stomach and duodenum. It has been shown, however, to be the dominant form lower down the gut.

LOCALISATION

Large amounts of somatostatin are found in the gastrointestinal system, including the pancreas, visceral autonomic nervous system, endocrine cells, and gut lumen. Immuno-
cytochemical studies show that somatostatin is localised to the D cells of the pancreas and gut mucosa, particularly in the gastric fundus, antrum, and duodenum. D cells are situated in the lower third of the crypts, from where they extend cytoplasmic processes along the basal membranes to the basal pole of neighbouring glands. Thus somatostatin is well placed to exercise paracrine control of other endocrine cells in the gut, for example, those responsible for the synthesis and release of gastrin. The D cells also have microvilli in direct contact with the lumen, thus providing a pathway by which changes in gut content can influence somatostatin production, either into the lumen or into the circulation. In addition, the gut is innervated by extrinsic and intrinsic somatostatin containing neurones, with the intrinsic neurones being present in both the submucosal and myenteric plexuses.

**ACTIONS**

These anatomical considerations explain how somatostatin can have multiple endocrine, paracrine, and exocrine functions, in addition to its central growth hormone release inhibiting effect. The first description of its gastrointestinal action was published within a year of the original paper. Somatostatin has long recognised inhibitory effects on pancreatic endocrine and exocrine secretion — that is, on insulin, glucagon, and pancreatic polypeptide — and also on pancreatic enzyme and bicarbonate responses to cholecystokinin and secretin, recently reviewed by Layer et al. It also inhibits the secretion of a wide variety of stimulatory gastrointestinal hormones, and decreases gastrointestinal motility and blood flow.

**STRUCTURE-FUNCTION RELATIONS**

The action of native somatostatin is brief and rapid, and is followed by rebound secretion, all of which suggests that it inhibits release rather than synthesis, perhaps by depressing exocytosis. Somatostatin receptors have been identified in the exocrine pancreas, on islet cells secreting insulin, glucagon and somatostatin, and on gastric cells. Binding of somatostatin to its receptor is accounted for primarily by the 4 amino acids in positions 7 to 10. In the late 1970s analogues were synthesised that were more specific in some respects than the native peptide, for example, more effective in inhibiting insulin than glucagon, and vice versa, while the structural requirements for gastrin inhibition seemed to differ from those required for action in the pituitary. It was found that duration of action, an important consideration for pharmacological investigation and therapeutic application, could be increased by substituting L-tryptophan for D-tryptophan in position 8. Preliminary results from human and animal studies with several different analogues were reported.

Intracellularly, somatostatin achieves its effects by cyclic AMP dependent and independent mechanisms and may act by affecting calcium transport through the cell membrane. Because somatostatin inhibits many aspects of cellular function, including endocrine secretion, muscular contraction, and cellular growth, it must antagonise a variety of intracellular signalling programmes. The dephosphorylation processes crucial for secretory activity intimately participate in inhibition by somatostatin at the molecular level. After binding to its receptor, somatostatin probably acts as a dephosphorylating agent to inhibit secretory processes, but whether the hormone also interacts with DNA to affect transcription is disputed.

Because of its many diverse physiological effects, native somatostatin has been investigated for the treatment of acromegaly and gut endocrine tumours. Despite its many potential uses, however, the clinical applications of somatostatin were limited by a very short half life of two to three minutes, necessitating continuous intravenous infusion and resulting in rebound hypersecretion of hormones after infusion.

**OCTREOTIDE**

Octreotide (Sandostatin) is an 8 amino acid synthetic peptide analogue engineered to overcome the limitations of native somatostatin. Octreotide retains the Phe-Trp-Lys-Thr portion of the native molecule (with the tryptophan residue in the D configuration), which is believed to constitute the essential pharmacophore and to be critical for specificity. Octreotide has greater pharmacological activity than the native molecule (being at least 20 times more potent in suppressing growth hormone secretion in vivo), is more selective for the inhibition of growth hormone than of insulin, and has a much enhanced duration of action (an elimination half life of 113 minutes compared with the two to three minutes of somatostatin). The synthetic molecule is sufficiently stable even to retain some activity on oral administration, the oral dose required to inhibit growth hormone secretion by 50% being 125 μg/kg after one hour.

As octreotide is incompletely absorbed after oral administration, investigation of its pharmacokinetic profile used intravenous and subcutaneous injection. Both routes of injection are well tolerated and the incidence of side effects is low. Moreover, bioavailability is similar by both routes of administration. Peak serum concentrations occur within 30 minutes after subcutaneous administration and within four minutes after a short (three minutes) intravenous infusion. Serum concentration of octreotide increases linearly with increasing doses, irrespective of whether the drug is given subcutaneously or intravenously. The average bioavailability of a subcutaneous dose is 100% or greater. Distribution is rapid. After a short (three minutes) intravenous infusion, a very rapid distribution phase (t½0, 0-142-0-210 h) is seen. Once in the blood, octreotide is distributed mainly in the plasma where it is 65% protein bound — mostly to lipoproteins, and to...
Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects

a lesser degree to albumin. The elimination half life (t½) of octreotide by either route of administration is approximately 1-5 hours – 30 times longer than that of somatostatin. About 32% of a subcutaneous dose is excreted in the urine as unchanged octreotide.

In patients with severe renal impairment, the plasma clearance of octreotide is reduced by 50%. This significant reduction points to the presence of a renal component in the elimination of the drug. Thus, when treating patients with renal impairment, the dose of octreotide should be carefully titrated.

Other notable findings reported in the original paper were that despite being much more potent than the native molecule, octreotide was better tolerated by laboratory animals, while preliminary trials in humans failed to identify any adverse effects up to the highest infused dose of 50 μg/hour (many times higher than the minimal effective dose for inhibiting arginine stimulated growth hormone release). The safety of octreotide was subsequently confirmed in a wide variety of clinical situations, particularly in two unexpected respects: firstly, most studies reporting the use of octreotide in infants have shown no inhibition of growth,16-41 while secondly, in contrast with the native molecule, rebound endocrine hypersecretion does not occur when octreotide is withdrawn.42

Octreotide inhibits normal growth hormone secretion in response to exercise, insulin induced hypoglycaemia, and arginine stimulation. Studies have shown that octreotide inhibits the release of thyroid stimulating hormone by thyrotrpin releasing hormone in healthy subjects. In both studies, the response of prolactin to thyrotrpin releasing hormone was not affected. Moreover, basal thyroid stimulating hormone concentration was unaffected in the absence of a thyrotropin releasing hormone challenge. Octreotide blunts the luteinising hormone response to luteinising hormone releasing hormone, but has no effect on the response of follicle stimulating hormone. Adrenocorticotropic hormone and cortisol concentrations do not change.

Octreotide exerts a number of pharmacological effects on the gastrointestinal tract. It considerably increases intestinal transit time and endogenous fluid secretion in the jejunum and ileum. As a result, absorption of water and electrolytes is increased.

Delay of intestinal transit time was shown in normal subjects undergoing steady state perfusion studies of the small bowel. Mean transit time through a 30 cm segment of jejunum was found to be increased from 4-0 to 17-0 minutes. Additionally, a significant decrease in endogenous flow from above the test segment was noted during the treatment period.43

Octreotide appreciably suppresses gastroenteropancreatic secretion, especially that of insulin, glucagon, pancreatic polypeptide, gastric inhibitory polypeptide, and gastrin. This action has been seen both before and after meals, but is less pronounced three hours after a meal, when physiological release of the peptides had already been completed.